Ketotifen

Ketotifen blocks histamine H1 receptors, preventing histamine‑mediated effects such as vasodilation and itching. It also stabilizes mast cells, limiting the release of inflammatory mediators like leukotrienes and cytokines. This dual action reduces the cascade of allergic inflammation and improves respiratory and ocular symptoms.

The appropriate dose of Ketotifen is determined by the prescribing healthcare professional based on the patient’s age, condition severity and response to therapy. Dosage may vary between oral tablets, syrup or other formulations, and should be followed exactly as directed on the prescription label.

Safety data for Ketotifen in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To request Ketotifen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with many first‑generation antihistamines, Ketotifen offers both H1‑receptor blockade and mast‑cell stabilization, which can provide longer‑lasting relief of allergic symptoms. However, it may cause more sedation than some second‑generation agents, so choice of therapy should consider efficacy, side‑effect profile and patient needs.

Ketotifen should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from excess moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Ketotifen is taken orally, usually with or without food, as directed by the prescriber. The tablet or liquid should be swallowed whole and not chewed, unless the formulation specifically allows it. Consistent timing each day helps maintain steady drug levels.

Serious adverse reactions, although rare, include severe skin reactions such as Stevens‑Johnson syndrome, anaphylaxis, hepatic injury and blood dyscrasias like agranulocytosis. Patients should seek immediate medical attention if they experience rash, difficulty breathing, jaundice or unexplained fatigue.

Individuals with known hypersensitivity to Ketotifen or any component of the formulation should not use the drug. Caution is also advised for patients with severe liver disease, uncontrolled asthma, or those taking interacting medications listed under major interactions.